SHCHealthcare · Diagnostics & ResearchThe 10 Wall Street analysts covering Sotera Health Co. hold a median 12-month price target of $22 — +34.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sotera Health Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (89): The share price has been relatively steady.
Accruals (55): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +34.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | JP Morgan | Downgrade | Underweight | $17 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $19 → $22 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | — |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $23 → $25 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $16 → $18 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $22 → $25 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 24 June 2026 | Barclays | Maintains | Overweight | $18 → $19 |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 5 June 2026 | Goldman Sachs | Initiates | Buy | — |
| 6 May 2026 | Piper Sandler | Reiterates | Overweight | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 24 Feb 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 9 Jan 2026 | RBC Capital | Reinstates | Outperform | $24 |
| 18 Dec 2025 | William Blair | Initiates | Outperform | — |
| 13 Nov 2025 | BMO Capital | Initiates | Outperform | — |
| 5 Nov 2025 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SHC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Sotera Health Co. returned −0.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 31% of US stocks
Cheaper than 14% of US stocks
Cheaper than 34% of US stocks
Higher than 38% of US stocks
Higher than 60% of US stocks
Higher than 68% of US stocks
Higher than 89% of US stocks
Higher than 76% of US stocks
Higher than 86% of US stocks
Higher than 90% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sotera Health Co. has a market value of $4.7B and an enterprise value of $6.4B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 4.4% year on year.
Net income over the same four quarters: $163.5M, a 13.4% net margin.
Diluted earnings per share, trailing twelve months: $0.57.
Free cash flow in the twelve months to 30 June 2026: $112.7M.
Trailing P/E: 27.3×; forward P/E: 15.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Sotera Health Co. employs 3,000 people — $405K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sotera Health Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Sotera Health Company’s Q3 2026 earnings call.
Why it matters — The transcript provides SHC watchers with the company’s remarks on its third-quarter results and related topics.
Sotera Health reported third-quarter 2026 revenue growth and higher adjusted EBITDA, and reaffirmed its full-year outlook. The company also cited softer European medical-device customer demand that began late in the quarter and continued into early Q4.
Why it matters — The update balances reported growth and unchanged guidance against a demand softness that carried into the next quarter.
Zacks Investment Research notes that Sotera Health’s Q3 top- and bottom-line results for the quarter ended September 2026 provide one view of performance, and points readers to key metrics compared with Wall Street estimates and year-ago values.
Why it matters — Those comparisons offer SHC watchers additional context for assessing quarterly performance beyond headline revenue and earnings figures.
Sotera Health Company reported quarterly earnings of $0.29 per share, above the Zacks Consensus Estimate of $0.27. Earnings were $0.26 per share a year earlier.
Why it matters — The report provides SHC watchers with an update on quarterly earnings compared with analyst consensus and the year-ago period.
Sotera Health reported third-quarter 2026 revenue growth of 4.4% and net income of $58 million, or $0.20 per diluted share. Adjusted EBITDA rose 3.9%, Adjusted EPS was $0.29, and the company reaffirmed its full-year 2026 revenue and Adjusted EBITDA growth outlooks.
Why it matters — The results and reaffirmed outlook provide SHC watchers an update on quarterly performance and management’s expectations for full-year growth.
The 10 Wall Street analysts covering Sotera Health Co. have a median 12-month price target of $22, with estimates ranging from $17 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Sotera Health Co., 8 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sotera Health Co. 87 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Sotera Health Co. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (89 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +34.3% from the last close, and Ticker Nerd's factor model ranks Sotera Health Co. 87 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sotera Health Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $25 over the next 12 months.
Sotera Health Co. returned -0.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Sotera Health Company is a healthcare services company that provides sterilization solutions, laboratory testing, and advisory services for medical device, pharmaceutical, life sciences, and food-related products. Through its Sterigenics, Nordion, and Nelson Labs businesses, the company supports product safety, contamination control, and regulatory compliance across critical stages of development and manufacturing.
The most recent item we track (Seeking Alpha, 3 Nov 2026): "Sotera Health Company (SHC) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Sotera Health Company’s Q3 2026 earnings call.
Sotera Health Company is a healthcare services company that provides sterilization solutions, laboratory testing, and advisory services for medical device, pharmaceutical, life sciences, and food-related products. Through its Sterigenics, Nordion, and Nelson Labs businesses, the company supports product safety, contamination control, and regulatory compliance across critical stages of development and manufacturing. Sterigenics offers outsourced terminal sterilization and irradiation services, Nordion supplies cobalt-60 and gamma irradiation technologies, and Nelson Labs delivers microbiological and analytical chemistry testing. Sotera Health serves customers in North America, Europe, and other international markets, making it an important provider of mission-critical services that help protect patients, consumers, and healthcare professionals.
CEO Mr. Alton E. Shader · 3,000 employees · United States · https://soterahealth.com
